Elliott Levy, M.D.
Venture Partner, 5AM Ventures

Elliott Levy, a drug developer and clinical trialist, joined the Kinaset Board in September 2023. Over the course of his career in pharmaceutical R&D, Elliott has played a significant role in the development of 22 approved medicines at two companies (Bristol Myers Squibb and Amgen), including the successful development of tezepelumab for severe asthma.

Elliott is currently a venture partner at 5AM Ventures, and an independent Director at Omega Therapeutics, Nucana plc, and Editas Medicines. He is a Senior Advisor at Boston Consulting Group, and also serves as a consultant and/or Advisory Board member for biotech firms developing innovative therapeutics in oncology, inflammation, and other disease areas.

Elliott graduated from Yale College magna cum laude and Yale Medical School cum laude.